{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:15:19Z","timestamp":1780085719350,"version":"3.54.0"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"\n Objective<\/jats:title>\n This study aimed to investigate the prevalence of Epstein\u2013Barr virus (EBV) infection in patients with childhood-onset systemic lupus erythematosus (cSLE) in Southwest China and to explore its associations with clinical manifestations, laboratory parameters, disease activity, and complications, particularly macrophage activation syndrome (MAS).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n A single-center, retrospective, cross-sectional study was conducted, enrolling 200 cSLE patients newly diagnosed at the Yunnan Provincial Children\u2019s Medical Center between January 2022 and June 2024. Based on EBV DNA levels tested at baseline (disease diagnosis) using real-time quantitative PCR (viral load \u2265 500 copies\/mL defined as positive), patients were categorized into an EBV-positive group (\n n<\/jats:italic>\n = 65) and an EBV-negative group (\n n<\/jats:italic>\n = 135). Demographic data, clinical manifestations, laboratory findings, disease activity (SLEDAI-2K score), and complications [MAS, lupus nephritis (LN), neuropsychiatric SLE (NPSLE), lupus pneumonitis] were compared between the two groups. Binary logistic regression analysis was used to identify independent risk factors for MAS.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The prevalence of EBV infection was 32.5% (65\/200). Compared to the EBV-negative group, the EBV-positive group had significantly higher frequencies of neurological symptoms (66.2% vs. 45.2%,\n P<\/jats:italic>\n = 0.007) and serous cavity effusion (60.0% vs. 43.7%,\n P<\/jats:italic>\n = 0.035). Laboratory analysis revealed significantly lower levels of complement C3 (\n P<\/jats:italic>\n = 0.032) and C4 (\n P<\/jats:italic>\n = 0.009), lower serum albumin (\n P<\/jats:italic>\n = 0.025), and higher blood urea nitrogen (BUN) (\n P<\/jats:italic>\n = 0.014) in the EBV-positive group. Most critically, the incidence of MAS was significantly higher in the EBV-positive group (15.4% vs. 6.7%,\n P<\/jats:italic>\n = 0.049). Multivariate analysis confirmed that EBV infection was an independent risk factor for MAS (OR = 2.90, 95% CI: 1.01\u20138.69,\n P<\/jats:italic>\n = 0.0497), while a higher platelet count was a protective factor (OR = 0.25, 95% CI: 0.07\u20130.75,\n P<\/jats:italic>\n = 0.0218). No significant differences were found between the groups regarding the prevalence of LN, NPSLE, lupus pneumonitis, or the overall SLEDAI-2K score.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n EBV infection is independently associated with an increased risk of MAS in cSLE patients and is linked to more pronounced complement consumption and specific clinical manifestations such as neurological symptoms and serositis. This study underscores the importance of EBV screening in cSLE patients for the early vigilance and management of MAS.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1714490","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T07:19:31Z","timestamp":1769411971000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical features and comorbidities of Epstein\u2013Barr virus infection in childhood-onset systemic lupus erythematosus with a focus on macrophage activation syndrome: a cross-sectional study of 200 patients"],"prefix":"10.3389","volume":"17","author":[{"given":"Hongye","family":"Wang","sequence":"first","affiliation":[{"name":"Nephrology, Rheumatology and Immunology Department, Kunming Children\u2019s Hospital (Children's Hospital Affiliated to Kunming Medical University)","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqian","family":"Zhouyang","sequence":"additional","affiliation":[{"name":"Nephrology, Rheumatology and Immunology Department, Kunming Children\u2019s Hospital (Children's Hospital Affiliated to Kunming Medical University)","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiran","family":"Yang","sequence":"additional","affiliation":[{"name":"Nephrology, Rheumatology and Immunology Department, Kunming Children\u2019s Hospital (Children's Hospital Affiliated to Kunming Medical University)","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhang","sequence":"additional","affiliation":[{"name":"Nephrology, Rheumatology and Immunology Department, Kunming Children\u2019s Hospital (Children's Hospital Affiliated to Kunming Medical University)","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helin","family":"Yan","sequence":"additional","affiliation":[{"name":"Nephrology, Rheumatology and Immunology Department, Kunming Children\u2019s Hospital (Children's Hospital Affiliated to Kunming Medical University)","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Nephrology, Rheumatology and Immunology Department, Kunming Children\u2019s Hospital (Children's Hospital Affiliated to Kunming Medical University)","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"Kunming Key Laboratory of Children Infection and Immunity, Yunnan Key Laboratory of Children's Major Disease Research, Yunnan Medical Center for Pediatric Diseases, Yunnan Institute of Pediatrics","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhao","sequence":"additional","affiliation":[{"name":"Nephrology, Rheumatology and Immunology Department, Kunming Children\u2019s Hospital (Children's Hospital Affiliated to Kunming Medical University)","place":["Kunming, Yunnan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-025-01242-0","article-title":"Advances in the treatment of systemic lupus erythematosus","volume":"24","author":"Scherlinger","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.1237","article-title":"POS0725 clinical and immunological characteristics of patients with juvenile-, adult- and late-onset systemic lupus erythematosus","volume":"80","author":"Iaremenko","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1136\/annrheumdis-2023-eular.2607","article-title":"POS0135 genetical and phenotypical findings of childhood-onset systemic lupus erythematosus","volume":"82","author":"Mor\u00e1n \u00c1lvarez","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2008.12.008","article-title":"Aberrant Epstein-Barr viral infection in systemic lupus erythematosus","volume":"8","author":"Poole","year":"2009","journal-title":"Autoimmun Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/v14040694","article-title":"Epidemiology of the epstein-barr virus in autoimmune inflammatory rheumatic diseases in northern Brazil","volume":"14","author":"Fran\u00e7a","year":"2022","journal-title":"Viruses"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.623944","article-title":"Epstein barr virus and autoimmune responses in systemic lupus erythematosus","volume":"11","author":"Jog","year":"2020","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1136\/annrheumdis-2020-eular.5703","article-title":"AB0395 systemic lupus associated macrophage activation syndrome \u2013 a single centre experience from India","volume":"79","author":"Acharya","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/20009666.2020.1787811","article-title":"Macrophage activation syndrome in a patient with systemic lupus erythematosus (SLE) and dual viremia","volume":"10","author":"Awasthi","year":"2020","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4103\/ijpm.ijpm_221_24","article-title":"EBV-triggered secondary macrophage activation syndrome in the backdrop of lupus in an adult","volume":"68","author":"Gohri","year":"2024","journal-title":"Indian J Pathol Micr"},{"key":"B10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/ijlh.13736","article-title":"Serious consequences of Epstein-Barr virus infection: Hemophagocytic lymphohistocytosis","volume":"44","author":"Xu","year":"2022","journal-title":"Int J Lab Hematol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10875-024-01701-0","article-title":"Single-cell transcriptomic analysis of epstein-barr virus-associated hemophagocytic lymphohistiocytosis","volume":"44","author":"Suzuki","year":"2024","journal-title":"J Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e1008365","DOI":"10.1371\/journal.ppat.1008365","article-title":"B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1\/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection","volume":"16","author":"Romero-Masters","year":"2020","journal-title":"PloS Pathog"},{"key":"B13","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1136\/annrheumdis-2020-eular.5553","article-title":"FRI0602-HPR persistent hypocomplementemia in patients with systemic lupus erythematosus","volume":"79","author":"Leguizam\u00f3n","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.651013","article-title":"Innate immune modulation induced by EBV lytic infection promotes endothelial cell inflammation and vascular injury in scleroderma","volume":"12","author":"Farina","year":"2021","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1714490\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:11:45Z","timestamp":1771924305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1714490\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":14,"alternative-id":["10.3389\/fimmu.2026.1714490"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1714490","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"article-number":"1714490"}}